Role of mri in patients with prostate carcinoma

A tétel rövid nézete
dc.contributor.advisorBerczi, Csaba
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Urológiai Klinikahu_HU
dc.contributor.authorHadjievangelou, Charalambos
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentNagy, Edit
dc.contributor.opponentDrabik, Gyula
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Radiológiai Klinikahu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Urológiai Klinikahu_HU
dc.date.accessioned2020-02-24T11:10:44Z
dc.date.available2020-02-24T11:10:44Z
dc.date.created2019-06-06
dc.description.abstractProstate cancer remains one of the major global health burdens, as it represents the second cause of cancer and the fifth leading cause of cancer-related death worldwide.The detection of PC is nowadays accomplished by prostate MRI and MRI-US fusion targeted biopsy, with the ultimate goal of reducing detection rates of clinically insignificant disease, increasing detection rates of clinically significant cancer, and better assessing disease size, grade, and location. Valuable information about the histopathological aggressiveness of a lesion can be provided with Multiparametric MRI, as well as the stage of a tumor with possible Ectracapsular extension can be assessed.MRI can aid patient selection for Active Surveillance, and therefore decrease misclassification rates, expand criteria to increase enrollment and limit the invasive follow-up nature of Active Surveillance.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent32hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/281210
dc.language.isoenhu_HU
dc.subjectMRIhu_HU
dc.subjectprostatehu_HU
dc.subjectcarcinomahu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleRole of mri in patients with prostate carcinomahu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)